{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:14:59Z","timestamp":1788869699126,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12350-020-02136-x","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T10:03:27Z","timestamp":1590573807000},"page":"2046-2055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Asystole following Regadenoson administration: Review of literature, risk factors and management"],"prefix":"10.1016","volume":"28","author":[{"given":"Talal","family":"Asif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lee Chuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s12350-014-9922-4","article-title":"Regadenoson for myocardial perfusion imaging: Is it safe?","volume":"21","author":"Hage","year":"2014","journal-title":"J Nucl Cardiol."},{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1007\/s12350-020-02136-x_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity","volume":"1","author":"Cerqueira","year":"2008","journal-title":"JACC Cardiovasc Imaging."},{"issue":"3","key":"10.1007\/s12350-020-02136-x_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12350-011-9373-0","article-title":"Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine","volume":"18","author":"Grady","year":"2011","journal-title":"J Nucl Cardiol."},{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s12350-014-9898-0","article-title":"Asystole following regadenoson infusion in stable outpatients","volume":"21","author":"Rosenblatt","year":"2014","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib6","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.ijcard.2014.07.058","article-title":"Advanced heart block and unresponsiveness after regadenoson administration during myocardial SPECT study","volume":"176","author":"Agarwal","year":"2014","journal-title":"Int J Cardiol."},{"issue":"3","key":"10.1007\/s12350-020-02136-x_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00259-013-2619-0","article-title":"Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy","volume":"41","author":"Brinkert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"10.1007\/s12350-020-02136-x_bib8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s12350-016-0755-1","article-title":"Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of","volume":"24","author":"Kureshi","year":"2017","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12350-019-01662-7","article-title":"Regadenoson-induced asystole and ischemic EKG changes in the setting of underlying coronary disease","volume":"27","author":"Mustehsan","year":"2019","journal-title":"J Nucl Cardiol."},{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s12350-018-1218-7","article-title":"Adverse effects associated with regadenoson myocardial perfusion imaging","volume":"25","author":"Andrikopoulou","year":"2018","journal-title":"J Nucl Cardiol."},{"key":"10.1007\/s12350-020-02136-x_bib11","unstructured":"Administration USFaD. https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/8eef7d83-7945-4091-b349-e5c41ed49f99\/state\/analysis. Accessed 20 Mar 2020."},{"issue":"7 Pt 1","key":"10.1007\/s12350-020-02136-x_bib12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jcmg.2019.01.017","article-title":"Severe Bradycardia and Asystole Following Regadenoson in Pharmacological Myocardial Perfusion Imaging: Cases and Treatment Recommendations","volume":"12","author":"Derbas","year":"2019","journal-title":"JACC Cardiovasc Imaging."},{"issue":"6","key":"10.1007\/s12350-020-02136-x_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s12350-012-9610-1","article-title":"Complete heart block associated with regadenoson: a real side effect","volume":"19","author":"Pandit","year":"2012","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12350-017-1081-y","article-title":"Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis","volume":"26","author":"Andrikopoulou","year":"2019","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12350-015-0294-1","article-title":"Conduction abnormalities during dipyridamole stress testing","volume":"24","author":"Massalha","year":"2017","journal-title":"J Nucl Cardiol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0735-1097(94)90424-3","article-title":"Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry","volume":"23","author":"Cerqueira","year":"1994","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10.1007\/s12350-020-02136-x_bib17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3892\/etm.2015.2279","article-title":"Electrocardiographic profile of adenosine pharmacological stress testing","volume":"9","author":"Sun","year":"2015","journal-title":"Exp Ther Med."},{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s12350-014-9968-3","article-title":"Regadenoson-induced bradycardia and hypotension: possible mechanism and antidote","volume":"21","author":"Underwood","year":"2014","journal-title":"J Nucl Cardiol."},{"issue":"5","key":"10.1007\/s12350-020-02136-x_bib19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12350-014-9985-2","article-title":"Serious complications associated with regadenoson administration for myocardial perfusion imaging: a commentary","volume":"21","author":"Hage","year":"2014","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1007\/s12350-020-02136-x_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3724\/SP.J.1263.2011.00184","article-title":"Use of antiarrhythmic drugs in elderly patients","volume":"8","author":"Lee","year":"2011","journal-title":"J Geriatr Cardiol."},{"issue":"18","key":"10.1007\/s12350-020-02136-x_bib21","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.jacc.2018.03.019","article-title":"Arrhythmias in Patients \u226580 Years of Age: Pathophysiology, Management, and Outcomes","volume":"71","author":"Curtis","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10.1007\/s12350-020-02136-x_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/0735-1097(94)90638-6","article-title":"Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study","volume":"23","author":"Manolio","year":"1994","journal-title":"J Am Coll Cardiol."},{"issue":"13","key":"10.1007\/s12350-020-02136-x_bib23","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/01.CIR.0000057811.86187.88","article-title":"Baroreflex buffering is reduced with age in healthy men","volume":"107","author":"Jones","year":"2003","journal-title":"Circulation."},{"issue":"11 Pt 2","key":"10.1007\/s12350-020-02136-x_bib24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1540-8159.1996.tb03241.x","article-title":"Changes in heart rate variability with age","volume":"19","author":"Reardon","year":"1996","journal-title":"Pacing Clin Electrophysiol."},{"issue":"1","key":"10.1007\/s12350-020-02136-x_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0733-8651(05)70054-0","article-title":"Cardiovascular pharmacology of aging","volume":"17","author":"Podrazik","year":"1999","journal-title":"Cardiol Clin."},{"issue":"7","key":"10.1007\/s12350-020-02136-x_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0091270007301620","article-title":"Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function","volume":"47","author":"Gordi","year":"2007","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"10.1007\/s12350-020-02136-x_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12350-012-9654-2","article-title":"The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation","volume":"20","author":"Doukky","year":"2013","journal-title":"J Nucl Cardiol."},{"issue":"1","key":"10.1007\/s12350-020-02136-x_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.amjcard.2009.08.663","article-title":"Safety of regadenoson in patients with end-stage renal disease","volume":"105","author":"Aljaroudi","year":"2010","journal-title":"Am J Cardiol."},{"issue":"4","key":"10.1007\/s12350-020-02136-x_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12350-011-9378-8","article-title":"Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis","volume":"18","author":"Palani","year":"2011","journal-title":"J Nucl Cardiol."},{"issue":"6","key":"10.1007\/s12350-020-02136-x_bib30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.amjcard.2009.11.042","article-title":"Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome","volume":"105","author":"Hage","year":"2010","journal-title":"Am J Cardiol."},{"issue":"4","key":"10.1007\/s12350-020-02136-x_bib31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1007\/s12350-020-02136-x_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","article-title":"ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers","volume":"23","author":"Henzlova","year":"2016","journal-title":"J Nucl Cardiol."}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-020-02136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-020-02136-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812301601X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107135812301601X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-020-02136-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:08:26Z","timestamp":1761026906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107135812301601X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S107135812301601X"],"URL":"https:\/\/doi.org\/10.1007\/s12350-020-02136-x","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asystole following Regadenoson administration: Review of literature, risk factors and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-020-02136-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}